Evidence map›Paper›PMID 35477069›Full record

ArticleEBioMedicine2022

Immune effects of CDK4/6 inhibitors in patients with HR

Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Silverio Tomao, Enrico Cortesi, Aurelia Rughetti and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Fabio ScirocchiDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Simone ScagnoliDepartment of Medical and Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome 00185, Italy.
Andrea BotticelliDepartment of Radiology, Oncology and Human Pathology, Policlinico Umberto I "Sapienza" University of Rome, Rome 00185, Italy. Electronic address: andrea.botticelli@uniroma1.it.
Alessandra Di FilippoDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Chiara NapoletanoDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Ilaria Grazia ZizzariDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Lidia StrigariMedical Physics Unit, "S. Orsola-Malpighi" Hospital, Bologna, Italy.
Silverio TomaoDepartment of Radiology, Oncology and Human Pathology, Policlinico Umberto I "Sapienza" University of Rome, Rome 00185, Italy.
Enrico CortesiDepartment of Radiology, Oncology and Human Pathology, Policlinico Umberto I "Sapienza" University of Rome, Rome 00185, Italy.
Aurelia RughettiDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Paolo MarchettiIDI-IRCCS, Via Monti di Creta 104, 00167 Roma, Italy.
Marianna NutiDepartment of Experimental Medicine, Laboratory of Tumor Immunology and Cell Therapy, Sapienza University of Rome, Rome 00161, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR

methodsImmune cell subsets were analysed using flow cytometry of peripheral blood mononuclear cells (PBMCs) isolated from patients with HR

findingsThe percentage of circulating Tregs and M/PMN-MDSCs was significantly downregulated from baseline during CDK4/6i-treatment (p<0.0001 and p<0.05, respectively). In particular, the effector Treg subset (CD4

interpretationCDK4/6i treatment results in downregulation of Tregs, M-MDSCs, and PMN-MDSCs, thus weakening tumour immunosuppression. This decrease is associated with response to treatment, highlighting the importance of unleashing immunity in cancer treatment efficacy. These results suggest a novel mechanism of immunomodulation in mBC and provide valuable information for the future design of novel treatments combining CDK4/6i with immunotherapy in other cancer settings.

fundingSapienza University of Rome.

Indexed as

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleForkhead Transcription FactorsHumansImmunosuppression TherapyLeukocytes, MononuclearProspective StudiesCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Forkhead Transcription FactorsCDK4/6iHR(+)/HER2(-) metastatic breast cancerImmune modulationMDSCsRegulatory T cellsTreg

Identifiers

PMID35477069
PMCPMC9061627
OpenAlexW4224871294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.